Loading…
Loading grant details…
| Funder | NATIONAL CANCER INSTITUTE |
|---|---|
| Recipient Organization | Massachusetts General Hospital |
| Country | United States |
| Start Date | Apr 01, 2024 |
| End Date | Mar 31, 2029 |
| Duration | 1,825 days |
| Number of Grantees | 1 |
| Roles | Principal Investigator |
| Data Source | NIH (US) |
| Grant ID | 10877369 |
Project Summary/Abstract The overarching goal of the proposed research is to elucidate the initiating mechanisms in the development of cancer-prone chronic inflammation for cancer prevention and therapy. Chronic inflammatory diseases, such as chronic dermatitis, pancreatitis, colitis and hepatitis, are major risk factors for cancer. In addition, a tumor-
promoting immune environment, which resembles chronic inflammation, is a key driver of cancer development across the majority of cancer types. By studying the mediators of the transition from acute to chronic inflammation, we have demonstrated that interleukin (IL)-33 cytokine is a key initiator of chronic inflammation
that eventually leads to cancer development in the skin, colon and pancreas. Importantly, we have recently discovered that the nuclear function of IL-33 within the epithelial cells plays an essential role in cancer development in chronic skin and pancreas inflammation. To develop an effective strategy to suppress cancer-
prone chronic inflammation, we will focus on the mechanism that blocks the initiating steps in the development of a cancer-prone chronic inflammation. Founded on our innovative discovery that IL-33 is an essential initiator of cancer-prone chronic inflammation, we aim to determine the mechanism of IL-33 induction in tissues exposed
to inflammatory insults and to develop a novel therapeutic approach to inhibit IL-33 expression for cancer prevention and therapy. To accomplish this, we will use novel mouse models and clinical samples to (1) determine the mechanism of IL-33 induction in chronic inflammation triggered by chemical agents, (2) investigate
the role of IL-33 in cancer-prone chronic inflammation associated with a viral infection, and (3) study inhibitor of IL-33 that can block chronic inflammation and the subsequent cancer development. The outcomes of our research will establish a fundamental pathway to suppress chronic inflammation-associated cancer and provide
the means to prevent cancer progression and recurrence.
Massachusetts General Hospital
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant